Rare Bleeding Disorders in the Netherlands (RBIN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03347591|
Recruitment Status : Recruiting
First Posted : November 20, 2017
Last Update Posted : August 31, 2018
Rationale: Rare bleeding disorders (deficiency of fibrinogen, factor II, V, V&VIII, VII, X, XI, XIII, α2-antiplasmin or plasminogen activator inhibitor 1) are not well defined with respect to their clinical phenotype, laboratory phenotype en genotype. At present, little is known about their clinical presentation, bleeding scores, bleeding episodes, health-related quality of life, laboratory parameters, genetics and current treatment. There are large differences in bleeding tendency and weak correlations with the level of factor deficiencies. Therefore, it is essential to perform thorough research in patients with rare bleeding disorders and perform laboratory and genetic tests, to seek explanations for the variety in clinical phenotype.
Objective: The purpose of the RBIN study is to describe the epidemiology, bleeding tendency, laboratory parameters, quality of life and genetics of all known patients in the Netherlands with rare bleeding disorders. In addition, the study aims to examine the relationship between clinical phenotype, laboratory phenotype and genotype.
Study design: explorative cross-sectional multicenter observational study Study population: all patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
Main study parameters/endpoints:
Description of the clinical phenotype, laboratory phenotype, genotype and quality of life.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: participating patients will be invited for one visit to their treatment center in order to draw blood, take a saliva sample and perform questionnaires. This will take approximately 40 to 120 minutes. Since the population of patients with rare bleeding disorders is very small it is important to include all patients, also minors (children <18 years), in the study (around one third of known patients are minors). Therefore, this study may be regarded as group-related. The risk associated with participation is negligible.
|Condition or disease||Intervention/treatment|
|Rare Bleeding Disorders||Genetic: WES Diagnostic Test: Several assays|
- Describe the epidemiology, clinical presentation, bleeding score, bleeding episodes, quality of life, laboratory parameters, genetics and treatment of homozygous and known heterozygous individuals (of all ages) with rare bleeding disorders (disorders of fibrinogen, FII, FV, FV & VIII, FVII, FX, FXI, FXIII, alpha-2-antiplasmin and PAI-1 deficiency) in the Netherlands;
- Examine the relationship between the clinical and laboratory presentation (clinical and laboratory phenotype), and between phenotypes and genetics (genotype);
- Examine the relationship between quality of life, phenotype and genotype;
- Validate the established factor activity levels for patients to remain without symptoms.
- Compare the clinical presentation, bleeding score, quality of life and laboratory parameters of individuals with a rare bleeding disorder (disorders of fibrinogen, FII, FV, FV & VIII, FVII, FX, FXI, FXIII, alpha-2-antiplasmin and PAI-1 deficiency) to those of individuals with haemophilia A or B in cooperation with the HIN-6 investigators
- Establish a firm base for a future Dutch registry for homozygous and known heterozygous individuals with rare bleeding disorders
- To develop a standard set of patient-reported, clinical and administrative data to be collected on a regular basis
- Liaise with the pro-RBDD study, a similar study in Italy, to work towards a pan-European study linking phenotype to genotype in individuals with rare bleeding disorders
- To assess if the NHA can distinguish mild clinical phenotypes in patients with similar factor activity levels
- To evaluate the usefulness of saliva coagulation biomarker tests in the management of patients with a rare bleeding disorder
- To examine whether age-dependent laboratory changes in factor concentrations and fibrinolysis occur in individuals with rare bleeding disorders and if so, whether they influence clinical phenotype
- To evaluate if patients with rare bleeding disorders are protected from arterial thrombosis
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Rare Bleeding Disorders in the Netherlands|
|Actual Study Start Date :||November 7, 2017|
|Estimated Primary Completion Date :||September 1, 2018|
|Estimated Study Completion Date :||September 1, 2018|
Patients with rare bleeding disorders
All patients registered in Dutch Haemophilia Treatment Centers with known disorders of the coagulation factors fibrinogen, factor II, V, V & VIII, VII, X, XI, XIII, α2-antiplasmin and plasminogen activator inhibitor type 1, aged 1 years and older.
136 bleeding related OMIM (Online Mendelian Inheritance in Man)-proved genes involved in haemostasis will be selected from Whole Exome Sequencing (WES)
Diagnostic Test: Several assays
Patients will be approached by their own treating physician. Data will be collected through questionnaires, a clinical interview, a blood and saliva sample obtained from each participant, and thorough review of electronic patient records. All procedures are study related. In case a physician visit with the treating physician is already planned, or in case a venepuncture for regular diagnostics or treatment is already planned, this can be combined with the study procedures to prevent an extra visit.
- Epidemiology [ Time Frame: 1 year ]Determine the prevalence of rare bleeding disorders in the Netherlands by evaluating all patients known in all Dutch Haemophilia Treatment Centers
- Phenotype [ Time Frame: 1 year ]Clinical phenotype will be measured by bleeding scores measured as ISTH-BAT.
- Laboratory phenotype [ Time Frame: 1 year ]Measure the factor concentrations of all patients known with a Rare Bleeding Disorder in the Netherlands
- Quality of Life [ Time Frame: 2 years ]Quality of life will be measured using the RAND-36 questionnaire
- Genotype [ Time Frame: 2 years ]Determine the genotype of patients (homozygous, heterozygous, compound heterozygous) by whole exome sequencing
- Minimum factor level [ Time Frame: 1 year ]The minimum factor level necessary to remain without bleeding will be calculated by measuring factor levels in all patients and their bleeding scores by ISTH-BAT
- Age [ Time Frame: 1 Year ]To examine whether age-dependent laboratory changes in factor concentrations and fibrinolysis occur in individuals with rare bleeding disorders and if so, whether they influence clinical phenotype.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03347591
|Contact: J. Saes, Drs.||0031243614794||Joline.Saes@radboudumc.nl|
|Contact: S. P. Smeekens, PhDfirstname.lastname@example.org|
|Academisch Medisch Centrum||Recruiting|
|Contact: Marjolein Peters, Dr. email@example.com|
|Den Haag, Netherlands, 2545AA|
|Contact: Paul Ypma P.Ypma@hagaziekenhuis.nl|
|Maxima Medisch Centrum||Recruiting|
|Eindhoven, Netherlands, 6500 PD|
|Contact: Laurens Nieuwenhuizen, PhD|
|University Medical Center Groningen (UMCG)||Recruiting|
|Contact: Vellenga, Prof MD PhD +31 (0)50 3613385 firstname.lastname@example.org|
|Principal Investigator: Vellenga, Prof MD PhD|
|Maastricht, Netherlands, 6202 AZ|
|Contact: Erik Beckers, Dr. email@example.com|
|Radboud university medical center||Recruiting|
|Nijmegen, Netherlands, 6525 GA|
|Contact: Postbus Trialbureau Hematologie-Oncologie +31 24 36 14 794 firstname.lastname@example.org|
|Principal Investigator: S. Schols, MD PhD|
|Rotterdam, Netherlands, 3000CA|
|Contact: Marjon Cnossen email@example.com|
|Principal Investigator:||S. Schols, PhD||Radboud University|